All Outputs (2)

Intraputamenal cerebral dopamine neurotrophic factor in Parkinson's disease: A randomized, double‐blind, multicenter phase 1 trial (2023)
Journal Article
Huttunen, H. J., Booms, S., Sjögren, M., Kerstens, V., Johansson, J., Holmnäs, R., …Svenningsson, P. (2023). Intraputamenal cerebral dopamine neurotrophic factor in Parkinson's disease: A randomized, double‐blind, multicenter phase 1 trial. Movement Disorders, 38(7), 1209-1222. https://doi.org/10.1002/mds.29426

Background: Cerebral dopamine neurotrophic factor (CDNF) is an unconventional neurotrophic factor that protects dopamine neurons and improves motor function in animal models of Parkinson's disease (PD). Objective: The primary objectives of this study... Read More about Intraputamenal cerebral dopamine neurotrophic factor in Parkinson's disease: A randomized, double‐blind, multicenter phase 1 trial.

The Bristol Bladder Trial: Five year outcomes in patients treated with neoadjuvant cabazitaxel and cisplatin chemotherapy for muscle invasive transitional cell carcinoma of the urinary bladder (2023)
Journal Article
Challapalli, A., White, P., Masson, S., Foulstone, E., Renninson, E., Bravo, A., …Bahl, A. (2023). The Bristol Bladder Trial: Five year outcomes in patients treated with neoadjuvant cabazitaxel and cisplatin chemotherapy for muscle invasive transitional cell carcinoma of the urinary bladder. Journal of Clinical Oncology, 41(6_suppl), 493-493. https://doi.org/10.1200/JCO.2023.41.6_suppl.493

Background: Neoadjuvant cisplatin-based combination chemotherapy (NAC) improves survival in muscle invasive bladder cancer (MIBC). However, response rates and survival remain suboptimal. We sought to evaluate the efficacy of cabazitaxel with cisplati... Read More about The Bristol Bladder Trial: Five year outcomes in patients treated with neoadjuvant cabazitaxel and cisplatin chemotherapy for muscle invasive transitional cell carcinoma of the urinary bladder.